Ebola Virus like particles (HA-EBOV) Sudan (Genebank: YP_138523.1)
A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) that are available for your initial testing from the Sudan Ebola strain (Genebank: YP_138523.1). These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs.
Size:
1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Available upon request. Store at -80°C.
Applications
Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Ebola Virus like particles (HA-EBOV) Zaire (Genebank: KJ660346.2)
A novel rapid hybrid alpha-pseudovirus for Ebolaviruses (EBOV) (HA-EBOV) from the Zaire strain that are available for your initial testing. These pseudoviruses are BSL2 safe and ready to use for studying viral entry. HAEBOV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs.
Size:
1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Available upon request. Store at -80°C.
Applications
Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Virus-like Particles (VLP’s) expressing recombinant Ebola virus (EBOV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40).
These VLP’s mimic Ebola virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and tool to enhance filovirus research.
Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Pathogen Strain: Zaire
Purification: Column chromatography
Expression: SF9 cells
Please note: After thawing, VLP’s tend to sediment to bottom of the tube and appear as aggregate pellet. Resuspend by gentle vortexing or pipetting up and down
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
HIV Virus like particle (VLP’s) expressing recombinant structural proteins
Safe for use in BSL-2 facilities.
Size:
1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Available upon request. Store at -80°C.
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Lentivirus vector pseudotyped with Influenza H5 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 5 x 10^4 RLU/µL.
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Lentivirus vector pseudotyped with Influenza H7 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 1 x 10^5 RLU/µL
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Marburg virus like particles (HA-MARV) MARV001 Isolate (Genebank: OL702894.1)
A novel rapid hybrid alpha-pseudovirus for Marburg (MARV) (HA-MARV) MARV001 Isolate that is available for your initial testing. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry. HA-MARV particles are pseudoviruses assembled from the structural proteins of the filovirus glycoprotein (GP), VP40 matrix protein, and the Nucleoprotein (NP) and package an alphaviral vector for reporter gene expression. The alpha-pseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entryinhibiting drugs.
Size:
1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Available upon request. Store at -80°C.
Applications
Marburg pseudovirus transduction of target cells for viral entry and functional studies
Rapid Anti-Marburg drug screening
Rapid Anti-Marburg neutralizing antibody
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Virus-like Particles (VLP’s) expressing recombinant Marburg (MARV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40).
Since these VLP’s mimic MARV (Musoke) virus but do not contain genetic material, thus are not infectious making an ideal candidate as a vaccine and a tool to enhance filovirus research.
Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term. Subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Pathogen Strain: Musoke
Purification: Column chromatography
Expression: SF9 cells
Please note: After thawing, VLP’s tend to sediment to the bottom of the tube and appear as aggregate pellet. VLP’s can be resuspended by gentle vortexing or by pipetting up and down, before use. Also, subaliquoting is recommended to avoid repeated freeze/thaw cycles.
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
Middle Eastern Respiratory Syndrome Corona Virus 2 (MERS-CoV-2) Virus Like Particle, Wild Type
The hybrid alpha-pseudovirus for MERS-CoV-2 (Ha-MERSCoV-2) is a newly developed MARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)pseudoviruses, Ha-MERS-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of MERS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle.
Size:
60X concentrated 5 x 100 µL
1x Conc. 25 x 200uL (~100 wells)
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Store at -80°C.
Applications:
Screening and quantification of anti-coronavirusneutralizing antibodies
Anti-coronavirus drug screening
Quantification of viral mutants’ infectivity
Identification of host co-factors and restriction factors of coronaviruses
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Nipah Virus-like particles (HA-NiV)
A novel rapid hybrid alpha-pseudovirus for Nipah virus (HA-NiV). HA-NiV particles are pseudoviruses assembled from the structural proteins of the Nipah virus, Fusion (F), Glycoprotein (G), Matrix (M), and Nucleocapsid (N) proteins and package an alphaviral vector for reporter gene expression. The alphapseudoviruses are single-cycle viruses with self-replicating RNA for rapid quantification of neutralizing antibodies and entry-inhibiting drugs. These pseudoviruses are BSL-2 safe and ready to use for studying viral entry.
Size:
1X concentrated 25 x 200 µL ~100 wells/96 well plate
Reporter: Available with Firefly luciferase, GFP, or RFP
Formulation & Storage: Store at -80°C.
Applications
Rapid NiV pseudovirus transduction of target cells for viral entry and functional studies
Anti-NiV drug screening
Anti-NiV neutralizing antibody screening
Intended for research use only, not for human, therapeutic, or diagnostic applications.
Recombinant Vesicular Stomatitis Virus pseudotyped MARV-Ci67 glycoprotein (rVSV pseudotyped MARV-Ci67 GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped Marburg-Musoke glycoprotein (rVSV-ΔG MARV-Musoke GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped Ravn virus glycoprotein (rVSV-ΔG RAVV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Ravn virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped MARV-Angola glycoprotein (rVSV pseudotyped MARVAngola GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped Sudan glycoprotein (rVSV pseudotyped SUDV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV pseudotypes containing the envelope glycoprotein of Sudan virus. Since the infectivity of rVSV pseudotyped SUDV GP is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
rVSV pseudotyped Sudan Virus GP (Gulu Strain) or Recombinant Vesicular Stomatitis Virus pseudotyped Sudan Virus Gulu glycoprotein (rVSV-SUDV-Gulu-GP)) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSVpseudotyped virus containing the envelope glycoprotein of Sudan virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.
Recombinant Vesicular Stomatitis Virus (rVSV) pseudotyped with Ebola virus glycoprotein (rVSV-EBOV-GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Ebola virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
